These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25405656)

  • 41. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry.
    Lee JM; Rhee TM; Hahn JY; Hwang D; Park J; Park KW; Kim HL; Kim SH; Chae IH; Doh JH; Jeon KH; Choi YJ; Park JS; Choi SH; Gwon HC; Koo BK; Alfonso F; Kim HS
    Int J Cardiol; 2017 Mar; 230():181-190. PubMed ID: 28043660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiographic and clinical outcome of percutaneous coronary intervention for in-stent restenosis of bifurcated lesions.
    Coroleu SF; De Vita M; Burzotta F; Trani C; Porto I; Niccoli G; Leone AM; Tommasino A; Talarico GP; Schiavoni G; Crea F
    EuroIntervention; 2012 Oct; 8(6):701-7. PubMed ID: 23086788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of Optimized Procedure-Related Factors in Drug-Eluting Balloon Angioplasty for Treatment of In-Stent Restenosis.
    Rhee TM; Lee JM; Shin ES; Hwang D; Park J; Jeon KH; Kim HL; Yang HM; Han JK; Park KW; Hahn JY; Koo BK; Kim SH; Kim HS
    JACC Cardiovasc Interv; 2018 May; 11(10):969-978. PubMed ID: 29798774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stent fracture is associated with a higher mortality in patients with type-2 diabetes treated by implantation of a second-generation drug-eluting stent.
    Ge Z; Liu ZZ; Kan J; Zhang JJ; Li SJ; Tian NL; Ye F; Qian XS; Yang S; Chen MX; Rab TS; Chen SL
    Int J Cardiovasc Imaging; 2017 Dec; 33(12):1873-1881. PubMed ID: 28631105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of 12-month angiographic outcomes between repeat drug-eluting stent implantation and drug-coated balloon treatment for restenotic lesion caused by stent fracture.
    Sakamoto Y; Yamawaki M; Araki M; Kobayashi N; Mori S; Tsutsumi M; Honda Y; Hirano K; Ito Y
    Heart Vessels; 2019 Oct; 34(10):1589-1594. PubMed ID: 30963303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.
    Claessen BE; Smits PC; Kereiakes DJ; Parise H; Fahy M; Kedhi E; Serruys PW; Lansky AJ; Cristea E; Sudhir K; Sood P; Simonton CA; Stone GW
    JACC Cardiovasc Interv; 2011 Nov; 4(11):1209-15. PubMed ID: 22115661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials.
    Elgendy IY; Mahmoud AN; Elgendy AY; Mojadidi MK; Elbadawi A; Eshtehardi P; Pérez-Vizcayno MJ; Wayangankar SA; Jneid H; David Anderson R; Alfonso F
    Cardiovasc Revasc Med; 2019 Jul; 20(7):612-618. PubMed ID: 30126824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of clinical outcomes of two different types of paclitaxel-coated balloons for treatment of patients with coronary in-stent restenosis.
    Nguyen VPT; Kim C; Hong SJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2019 Sep; 34(9):1420-1428. PubMed ID: 30903315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
    Chen SL; Sheiban I; Xu B; Jepson N; Paiboon C; Zhang JJ; Ye F; Sansoto T; Kwan TW; Lee M; Han YL; Lv SZ; Wen SY; Zhang Q; Wang HC; Jiang TM; Wang Y; Chen LL; Tian NL; Cao F; Qiu CG; Zhang YJ; Leon MB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1266-76. PubMed ID: 25326748
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.
    van Houwelingen KG; van der Heijden LC; Lam MK; Kok MM; Löwik MM; Louwerenburg JW; Linssen GC; IJzerman MJ; Doggen CJ; von Birgelen C
    Heart Vessels; 2016 Nov; 31(11):1731-1739. PubMed ID: 26747438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential Prognostic Effect Between First- and Second-Generation Drug-Eluting Stents in Coronary Bifurcation Lesions: Patient-Level Analysis of the Korean Bifurcation Pooled Cohorts.
    Lee JM; Hahn JY; Kang J; Park KW; Chun WJ; Rha SW; Yu CW; Jeong JO; Jeong MH; Yoon JH; Jang Y; Tahk SJ; Gwon HC; Koo BK; Kim HS
    JACC Cardiovasc Interv; 2015 Aug; 8(10):1318-1331. PubMed ID: 26315734
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug eluting stents for the treatment of bare metal in-stent restenosis: long-term outcomes in real world practice.
    Appleby CE; Khattar RS; Morgan K; Clarke B; Curzen N; Neyses L; Fath-Ordoubadi F
    EuroIntervention; 2011 Jan; 6(6):748-53. PubMed ID: 21205600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy and safety of Zotarolimus-eluting stent in patients with diabetes mellitus: pooled 5-year results from the ENDEAVOR III and IV trials.
    Vardi M; Burke DA; Bangalore S; Pencina MJ; Mauri L; Kandzari DE; Leon MB; Cutlip DE
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1031-8. PubMed ID: 23737390
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry.
    Kutcher MA; Brennan JM; Rao SV; Dai D; Anstrom KJ; Mustafa N; Sedrakyan A; Booth ME; Douglas PS; Messenger JC
    Catheter Cardiovasc Interv; 2014 Feb; 83(2):171-81. PubMed ID: 23907981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.